

Please type a plus sign (+) inside this box → [+]



PTO/SB08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 1

COMPLETE IF KNOWN

Application Number	09/996,657
Confirmation Number	6277
Filing Date	November 29, 2001
First Named Inventor	Charles R. Degenhardt
Group Art Unit	1625
Examiner Name	R. Desai
Attorney Docket Number	8375D

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	U.S. PATENT DOCUMENT Number ² Kind Code ³ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
<i>RD</i>	1	6,376,514 B1	Degenhardt et al.	04/23/2002	

RECEIVED
JUL 6 3 2002
FBI CENTER 1600 2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT Office ² Number ³ Kind Code ⁴ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁵
<i>RD</i>	2	WO 00/18733 A1	Procter & Gamble	04/06/2000		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁵
EXAMINER	<i>RD</i>	DATE CONSIDERED	<i>11-14-2002</i>

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.

COPY OF PAPERS
ORIGINALLY FILED

LIST OF DOCUMENTS CITED BY APPLICANTS (Use several sheets if necessary)	ATTY. DOCKET NO. 8375		SERIAL NO. 09/740,643	
	APPLICANT Degenhardt et al			
	FILING DATE 12/19/2000		GROUP 1646	



U. S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
RO	1	4,923,871	5/8/1990	Inaba et al	C07D	401/04	
RO	2	4,985,558	1/15/1991	Suzuki et al	C07D	401/04	
RO	3	4,996,321	2/26/1991	Baldwin et al	C07D	211/70	
RO	4	5,114,919	5/19/1992	Baldwin et al	A61K	31/55	
RO	5	5,124,339	6/23/1992	KING	A01N	43/36	
RO	6	5,130,303	7/14/1992	Akiyama et al	A61K	31/44	
RO	7	5,160,727	11/3/1992	Klohs et al	A61K	49/00	
RO	8	5,173,486	12/22/1992	Monkovic et al	A61K	31/55	
RO	9	5,182,293	1/26/1993	Sunkara et al	A61K	31/44	
RO	10	5,190,946	3/2/1993	Ramu et al	A61K	31/495	
RO	11	5,190,957	3/2/1993	Sunkara et al	A61K	31/47	
RO	12	5,204,348	4/20/1993	Fukazawa et al	A61K	31/495	
RO	13	5,216,172	6/1/1993	TOYOTA ET AL	C07D	213/55	
RO	14	5,225,405	7/6/1993	Paramelle et al	A01N	55/02	
RO	15	5,238,936	8/24/1993	Regnier et al	C07D	401/04	
RO	16	5,272,159	12/21/1993	Baldwin et al	A61K	31/435	
RO	17	5,292,726	3/8/1994	Ashton et al	A61K	31/675	
RO	18	5,292,757	3/8/1994	OHSUMI ET AL	C07D	211/90	
RO	19	5,302,727	4/12/1994	Eliason et al	C07D	339/08	
RO	20	5,336,685	8/9/1994	Prochaska et al	A61K	31/35	
RO	21	5,362,729	11/8/1994	Cozzi et al	C07D	401/06	
RO	22	5,371,081	12/6/1994	Houghton et al	A61K	31/535	
RO	23	5,389,644	2/14/1995	Peglion et al	A61K	31/44	
RO	24	5,409,690	4/25/1995	Howell et al	A61K	48/00	
RO	25	5,416,091	5/16/1995	KING	A61K	45/06	
RO	26	5,436,243	7/25/1995	Sachs et al	A61K	31/135	
RO	27	5,508,403	4/16/1996	Akiyama et al	C07F	9/6574	
RO	28	5,514,664	5/7/1996	Ulrich	A61K	31/70	
RO	29	5,516,775	5/14/1996	Zimmermann et al	A61K	31/505	
RO	30	5,521,184	5/28/1996	Zimmermann	C07D	239/92	
RO	31	5,523,304	6/4/1996	Sunkara	A61K	31/435	
RO	32	5,525,606	6/11/1996	Moschel et al	A61K	31/52	
RO	33	5,536,722	7/16/1996	Coe et al	C07D	251/70	
RO	34	5,541,232	7/30/1996	Howell et al	A61K	31/045	
RO	35	5,543,423	8/6/1996	Zelle et al	A61K	31/44	
RO	36	5,543,428	8/6/1996	Sawyer et al	A61K	31/35	
RO	37	5,550,149	8/27/1996	Powell et al	C07D	209/44	
RO	38	5,569,471	10/29/1996	Oguro	A61K	33/24	
RO	39	5,571,687	11/5/1996	Casey et al	C12Q	1/00	
RO	40	5,583,137	12/10/1996	Coe et al	C07D	473/16	
RO	41	5,610,165	3/11/1997	MacCoss et al	A61K	31/445	
RO	42	5,620,971	4/15/1997	ARMISTEAD ET AL	A61K	31/54	
RO	43	5,622,953	4/22/1997	Janssen et al	A61K	31/495	
RO	44	5,643,869	7/1/1997	Dreyfuss et al	A61K	38/00	
RO	45	5,654,304	8/5/1997	Pfister et al	A61K	31/50	
RO	46	5,663,179	9/2/1997	Dumaitre et al	C07D	401/12	
RO	47	5,670,508	9/23/1997	Wang et al	A61K	31/535	
RO	48	5,670,521	9/23/1997	Freedman et al	A01K	31/445	
RO	49	5,700,826	12/23/1997	Mjalli et al	A01K	31/415	
RO	50	5,723,459	3/3/1998	Armistead et al	A61K	31/54	
RO	51	5,726,184	3/10/1998	Zelle	C07D	217/00	
RO	52	5,733,911	3/31/1998	Eilon et al	A61K	31/495	
RO	53	5,744,485	4/28/1998	Zelle et al	C07D	211/32	
RO	54	5,756,475	5/26/1998	Inomata et al	A01N	43/04	

RECEIVED
JUN 16 2002
ENTER 16002900

RECEIVED
JUN 16 2002
ENTER 16002900



COPY OF PAPERS
ORIGINALLY FILED

P&G Case 8375
FORM PTO-1449
Sheet 3 of 10

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RO	1	Pajeva, I. et al, "A Comparative Molecular Field Analysis of Propafenone-type Modulators of Cancer Multidrug Resistance". <i>Quant. Struct. - Act. Relat.</i> , 17, pg. 301-312, (1998)
RO	2	Roe, M. et al, "Reversal of P-Glycoprotein Mediated Multidrug Resistance by Novel Anthranilamide Derivatives", <i>Bioorganic & Medicinal Chemistry Letter</i> , 9, pg 595-600, (1999)
RO	3	Chiba, P. et al, "Synthesis, Pharmacologic Activity, and Structure - Activity Relationships of a Series of Propafenone-related modulators of Multidrug Resistance", <i>J. Med. Chemistry</i> , 38, pg. 2789-2793, (1995)
R	4	Ecker, G. et al, "Structure - Activity Relationship Studies on Benzofuran Analogs of Propafenone-type Modulators of Tumor Cell Multidrug Resistance", <i>Journal of Medicinal Chemistry</i> , 39, pg. 4767-4774 (1996)
RO	5	Chiba, P. et al "Structural Requirements for Activity of Propafenone-type Modulators in P-Glycoprotein-Mediated Multidrug Resistance." <i>Molecular Pharmacology</i> , 49, pg. 1122-1130, (1996)
R	6	Chiba, P. et al "Synthesis and Pharmacological activity of the stereoisomers of GP-88, a Propafenone-type modulator of Multidrug resistance", <i>Bioorganic & Medicinal Chemistry Letter</i> , 8, pg 829-832, (1998)
RO	7	Chiba, P. et al, "Studies on Propafenone-type Modulators of Multidrug Resistance III: Variations on the Nitrogen", <i>Quant. Struct.-Act. Relat.</i> 16, pg. 361-366 (1997)
RO	8	Chiba, P. et al "Studies on Propafenone-type Modulators of Multidrug-resistance IV: Synthesis and Pharmacological Activity of 5-Hydroxy and 5-Benzoyloxy", <i>Arch. Pharm. Pharm. Med. Chem.</i> , 330, pg. 343-347 (1997)
RO	9	Oberlies, N. et al, "Structure - Activity Relationships of Diverse Annonaceous Acetogenins against Multidrug Resistant Human mammary Adenocarcinoma (MCF-7/Adr) Cells", <i>Journal of Medicinal Chemistry</i> , 40, pg. 2102-2106, (1997)
RO	10	Conseil, G. et al, "Flavonoids: A class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein", <i>Biochemistry</i> , 95, pg. 9831-9836, (1998)
RO	11	Ferte, J. et al, "Flavonoid-Related Modulators of Multidrug Resistance: Synthesis, Pharmacological Activity, and Structure - Activity Relationships", <i>J. Med. Chemistry</i> , 42, pg. 478-489 (1999)
RO	12	Meritt, J. et al, "The bisindolylmaleimide protein kinase C inhibitor, Ro 32-2241, reverses multidrug resistance in KB tumor cells", <i>Cancer Chemother Pharmacol</i> , 43, pg. 371-378, (1999)
RO	13	Payen, L. et al, "Reversal of MRP-Mediated Multidrug Resistance in Human lung Cancer Cells by the Antiprogesterin Drug RU486" <i>Biochemical and Biophysical Research Communications</i> , 258, pg. 513-518, (1999)
RO	14	Fukushima, T et al, "Effect of PSC 833 on the cytotoxicity of idarubicin and idarubicinol in the multidrug-resistant K562 cells". <i>Leukemia Research</i> , 23, pg. 37-42, (1999)
RO	15	Berger, D. et al, "Novel Multidrug Resistance Reversal Agents", <i>Journal Medicinal Chemistry</i> , 42, pg. 2145-2161, (1999)
RO	16	Roe, M. et al, "Reversal of P-Glycoprotein Mediated Multidrug Resistance by Novel anthranilamide Derivatives", <i>Bioorganic & Medicinal Chemistry Letters</i> , 9, pg. 595-600, (1999)
RO	17	Chiba, P. et al, "Substituted 4-Acylpyrazoles and 4-Acylpyrazolones: Synthesis and Multidrug Resistance-Modulating Activity". <i>J. Med. Chem.</i> , 41, pg. 4001-4011, (1998)
RO	18	Sawanishi, H. et al, "Novel Inhibitors for Multidrug Resistance: 1,3,5-Triazacycloheptanes", <i>J. Med. Chem.</i> , 38, pg. 5066-5070, (1995)
RO	19	Dhainaut, A. et al, "New Purines and Purine Analogs as Modulators of Multidrug Resistance", <i>J. Med. Chem.</i> , 39, pg. 4099-4108, (1996)
RO	20	Suzuki, T. et al, "Structure - Activity Relationship of Newly Synthesized Quinoline derivatives for Reversal of Multidrug Resistance in Cancer", <i>Journal of Medicinal Chemistry</i> , 40, pg. 2047-2052, (1997)
RO	21	Dinh, T. et al, "Design, Synthesis, and Evaluation of the Multidrug Resistance-Reversing activity of D-Glucose Mimetics of Hapalosin", <i>Journal of Medicinal Chemistry</i> , 41, pg. 981-987 (1998)
RO	22	Dinh, T. et al, "Synthesis, Conformational Analysis, and Evaluation of the Multidrug Resistance-Reversing Activity of the Triamide and Proline Analogs of Hapalosin", <i>J. of Organic Chemistry</i> , 62, pg. 6773-6783, (1997)
RO	23	Dhainaut, A. et al, "New Triazine derivatives as Potent Modulators of Multidrug Resistance", <i>Journal of Medicinal Chemistry</i> , 35, pg. 2481-2496, (1992)
RO	24	Thimmaiah, K. et al. "Synthesis and Chemical Characterization of N-Substituted Phenoxazines Directed toward Reversing Vinca Alkaloid Resistance in Multidrug-Resistance Cancer Cells", <i>Journal of Medicinal Chemistry</i> , 35, pg. 3358-3364, (1992)
RO	25	Bois, F. et al, "Halogenated Chalcones with High-Affinity Binding to P-Glycoprotein: Potential Modulators of Multidrug Resistance", <i>Journal of Medicinal Chemistry</i> , 41, pg. 4161-4164 (1998)
RO	26	Emmer, G. et al, "Derivatives of a Novel Cyclopeptolide. 2. Synthesis, Activity against Multidrug Resistance in CHO and KB cells <i>in Vitro</i> , and Structure-Activity Relationships", <i>Journal of Medicinal Chemistry</i> , 37, pg. 1918-1928 (1994)
RO	27	Andrus, M. et al, "Total Synthesis of Stipiamide and designed Polyenes as new Agents for the Reversal of Multidrug Resistance", <i>J. American Chemical Society</i> , 119, pg. 12159-12169 (1997)

JUL 0 3 2002

RECEIVED




COPY PAPERS
ORIGINALLY FILED

RECEIVED 375
1449
Sheet 4 of 10
JUL 03 2002

OTHER DOCUMENTS Continued

RO	28	Tasaka, S et al, "Synthesis of 2-Phenylimidazo [2,1-b]benzothiazole Derivatives as Modulators of Multidrug Resistance for Tumor Cells", <i>J. Heterocyclic Chem.</i> , 34, pg. 1763-1767 (1997)
RO	29	Monihira, K. et al, "Synthesis and Evaluation of Artificial Taxoids with Antitumor and Multi-Drug resistance Reversing Activities", <i>Bioorganic & Medicinal Chemistry Letters</i> , 8, pg. 2977-2982 (1998)
RO	30	Monihira, K. et al, "Synthesis of C-Ring Aromatic Taxoids and Evaluation of Their Multi-Drug Resistance reversing activity", <i>Bioorganic & Medicinal Chemistry Letters</i> , 8, pg. 2973-2976, (1998)
RO	31	Kobayashi, J. et al, "Modulation of the Multidrug Resistance by a Taxus sp. C and Other Taxoids from Japanese Yew", <i>Bioorganic & Medicinal Chemistry Letters</i> , 8, pg. 1555-1558, (1998)
RO	32	Kobayashi, J. et al, "Effects of Taxoids from <i>taxus cuspidata</i> on microtubule depolymerization and vincristine accumulation in MDR cells", <i>Bioorganic & Medicinal Chemistry Letters</i> , 7, pg. 393-398 (1997)
RO	33	Hosoyama, H. et al, "Modulation of Multidrug Resistance in Tumor Cells by Taxinine derivatives", <i>Bioorganic & Medicinal Chemistry Letters</i> , 9, pg. 389-394, (1999)
RO	34	Kam, T. et al, "Reversal of Multidrug resistance (MDR) by aspidofractinine-type indole alkaloids", <i>Bioorganic & Medicinal Chemistry Letters</i> , 8, pg. 2769-2772, (1998)
RO	35	Tanabe, H. et al, "Newly Synthesized Dihydropyridine Derivatives as Modulators of P-Glycoprotein-mediated Multidrug Resistance", <i>Bioorganic & Medicinal Chemistry Letters</i> , 6, pg. 2219-2227 (1998)
RO	36	Sawanishi, H. et al, "Structure-activity Relationships of Diamines, Dicarboxamides, and Disulfonamides on Vinblastine accumulation in P388/ADR Cells", <i>Chem. Pharm. Bull.</i> , 7, pg. 1459-1462, (1994)
RO	37	Hooijberg, J. et al, "Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein", <i>FEBS Letters</i> , 413, pg. 344-348, (1997)
RO	38	Sarkadi, B. et al, "Interaction of bioactive hydrophobic peptides with the human multidrug transporter", <i>Th FASEB Journal</i> , 8, pg. 766-770, (1994)
RO	39	Pereira, E. et al, "Reversal of Multidrug Resistance by Verapamil analogues", <i>Biochemical Pharmacology</i> , vol. 50, no. 4, pg. 451-457, (1995)
RO	40	Pommerenke, E. et al, "Activity of various amphiphilic agents in reversing multidrug resistance of L1210 cells", <i>Cancer Letters</i> , 55, pg. 17-23, (1990)
RO	41	Kiue, A. et al, "Activities of Newly Synthesized Dihydropyridines in Overcoming of Vincristine Resistance, Calcium Antagonism, and Inhibition of Photoaffinity labeling of P-Glycoprotein in Rodents" <i>Cancer Research</i> , 50, pg. 310-317, (1990)
RO	42	Ford, J. et al, "Structural Features Determining Activity of Phenothiazines and Related Drugs for Inhibition of Cell Growth and Reversal of Multidrug resistance", <i>Molecular Pharmacology</i> , 35, pg. 105-115
RO	43	Nogae, I. et al, "Analysis of structural features of dihydropyridine analogs needed to reverse multidrug resistance and to inhibit photoaffinity labeling of P-glycoprotein", <i>Biochemical Pharmacology</i> , 38, pg. 519-527, (1989)
RO	44	Pearce, H. et al, "Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance", <i>Proc. Natl. Acad. Sci.</i> , 86, pg. 5128-5132 (1989)
RO	45	Kirk, J. et al, "Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives.", <i>Biochemical Pharmacology</i> , 48, pg. 277-285, (1994)
RO	46	Gekeler, V. et al, "The specific bisindolymaleimide PKC-inhibitor GF 109203x efficiently modulates MRP-Associated Multiple drug resistance", <i>Biochemical and Biophysical research communications</i> , 206, pg. 119-126, (1995)
RO	47	Ford, J. et al, "Cellular and Biochemical Characterization of Thioxanthines for Reversal of Multidrug resistance in Human and Murine Cell Lines", <i>Cancer Research</i> , 50, pg. 1748-1756, (1990)
RO	48	Kadam, S. et al, "Reversal of Multidrug Resistance by Two Novel Indole Derivatives", <i>Cancer Research</i> , 52, pg. 4735-4740, (1992)
RO	49	Dellinger, M. et al, "Structural Requirements of Simple Organic Cations for Recognition by Multidrug-resistant cells", <i>Cancer research</i> , 52, pg. 6385-6389, (1992)
RO	50	Horton, J. et al, "Pharmacological Characterization of N-Substituted Phenoxazines Directed toward reversing vinca alkaloid resistance in multidrug-resistant cancer cells", <i>Molecular Pharmacology</i> , 44, pg. 552-559, (1993)
RO	51	Smith, C. et al, "Welwitindolinone Analogues that reverse P-Glycoprotein-Mediated Multiple drug Resistance", <i>Molecular Pharmacology</i> , 47, pg. 241-247, (1995)
RO	52	Zhang, L. et al, "Characterization of Prenylcysteines that interact with P-glycoprotein and inhibit drug transport in tumor cells", <i>The Journal of Biological Chemistry</i> , 270, pg. 22859-22865 (1995)
RO	53	Hofmann, J. et al, "Mechanism of action of dexniguldipine-HC1 (B8509-035), a new potent modulator of multidrug resistance" <i>Biochemical Pharmacology</i> , 49, pg. 603-609 (1995)
RO	54	Wakusawa, S. et al, "Overcoming of Vinblastine Resistance by Isoquinolinesulfonamide compounds in Adriamycin-Resistant Leukemia Cells" <i>Molecular Pharmacology</i> , 41, 1034-1038 (1992)
RO	55	Eliason, J. et al, "Novel Dithiane analogues of tiapamil with high activity to overcome multidrug resistance in vitro", <i>Biochemical Pharmacology</i> , 50, pg. 187-196, (1995)
RO	56	Bhat, U. et al, "A structure-Function Relationship among Reserpine and Yohimbine Analogues in Their Ability to Increase expression of mdr1 and P-Glycoprotein in a human colon carcinoma cell line" <i>Molecular Pharmacology</i> , 48, pg. 682-689 (1995)

COPY PAPERS
ORIGINALLY FILEDRECEIVED
P&G Cas 8375
Sheet 5 of 10

OTHER DOCUMENTS Continued

JUL 03 2002

RO	57	Borr I, M. et al, "The effect of crown th rs, tetraalkylammonium salts, and polyethylene amphiphiles on pirarubicin incorporation in K562 resistant cells" <i>Biochemical Pharmacology</i> , 50, pg. 1245-1255, (1995)
RO	58	T ffoli, G. et al, "Structure-Actvty r lationship of v rapamil analogs and reversal of multidrug resistance" <i>Biochemical Pharmacology</i> , 50, pg. 1245-1255, (1995)
RO	59	Christensen, J. et al, "Resersal of multidrug resistance <i>in vivo</i> by dietary administration of the phytochemical Indole-3-Carbinol", <i>Cancer Research</i> , 56, pg. 574-581, (1996)
RO	60	Barnes, K. et al, "Steroid Transport, accumulation, and antagonism of P-Glycoprotein in Multidrug resistant cells" <i>Biochemistry</i> , 35, pg. 4820-4827, (1996)
RO	61	Frappier, F. et al, "Bisbenzylisoquinolines as Modulators of Chloroquine Resistance in <i>Plasmodium falciparum</i> and multidrug resistance in Tumor cells" <i>Antimicrobial Agents and Chemotherapy</i> , June, pg. 1476-1481, (1996)
RO	62	Nakamura, S. et al, "Inhibition of P-Glycoprotein-Dependent Multidrug Resistance by an Isoquinolinesulfonamide Compound H-87 in Rat Ascites Hepatoma AH66 Cells" <i>Biol. Pharm. Bull.</i> , 19, pg. 886-889, (1996)
RO	63	Hidaka, H. et al, "Isoquinolinesulfonamides, Novel and Potent Inhibitors of Cyclic Nucleotide dependent Protein Kinase and Protein Kinase C", <i>Biochemistry</i> , 23, pg. 5036-5041, (1984)
RO	64	Chou, T. et al, "Reversal of anticancer multidrug resistance by the ardeemins" <i>Proc. Natl. Acad. Sci.</i> , 95, pg. 8369-8374, (1998)
RO	65	Vanhoefer, U. et al, "PAK-104P, a Pyridine analogue, Reverses Paclitaxel and Doxorubicin Resistance in cell Lines and Nude Mice Bearing Xenografts that overexpress the multidrug resistance protein" <i>Clinical Cancer Research</i> , 2, pg. 369-377 (1996)
RO	66	Chaundhary, P. et al, " Induction of Multidrug Resistance in Human Cells by Transient Exposure to differ nt Chemotherapeutic Drugs" <i>Journal of the National Cancer Institute</i> , 85, pg. 632-639 (1993)
RO	67	Sharom, F. et al, "Linear and cyclic peptides as substrates and modulators of P-glycoprotein: peptide binding and effects on drug transport and accumulation" <i>Biochem. Journal</i> , 333, pg. 621-630 (1998)
RO	68	Desrayaud, S. et al, "Effect of the Mdr1a P-Glycoprotein Gene disruption on the tissue distribution of SDZ PSC 833, a multidrug Resistance-Reversing Agent, In Mice." <i>The Journal of Pharmacology and experimental Therapeutics</i> , 285, pg. 438-443 (1998)
RO	69	Watanabe, T. et al, "Effect of SDZ PSC 833 ([3'-keto-Bmt]-[Val]-cyclosporin) on serum protein binding and distribution to blood cells of doxorubicin, vincristine and etoposide <i>in vitro</i> " <i>Anti-Cancer Drugs</i> , 8, pg. 400-404 (1997)
RO	70	Germann, U. et al, "Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance <i>in vitro</i> " <i>Anti-cancer drugs</i> , 8, pg. 125-140 (1997)
RO	71	Shah, A. et al, "6,12-Dihydro-1-benzopyrano [3,4-b][1,4] benzothiazin-6-ones: Synthesis and <i>mdr</i> Reversal in Tumor Cells" <i>Anticancer Research</i> , 18, pg. 3001-3004 (1998)
RO	72	Pajeva, I. et al, " Molecular Modeling of Phenothiazines and Related Drugs as multidrug resistance modifiers: A Comparative molecular field analysis study" <i>Journal of Medicinal Chemistry</i> , 41, pg. 1815-1826 (1998)
RO	73	Pajeva, I. et al, " QSAR and Molecular Modelling of Catamphiphilic Drugs Able to Modulate Multidrug resistance in Tumors" <i>Quant. Struct. - Act. Relat.</i> , 16, pg. 1-10 (1997)
RO	74	Atadja, P. et al, "PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance", <i>Cancer and Metastasis Reviews</i> , 17, pg. 163-168, (1998)
RO	75	Fields, A. et al, " PSC833: initial clinical results in refractory ovarian cancer patients" <i>Current Opinion in Oncology</i> , 10, pg. S21 (1998)
RO	76	Demeule, M. et al, "Molecular Interactions of Cyclosporin A with P-glycoprotein" <i>The Journal of Biological Chemistry</i> , 272, pg. 6647-6652 (1997)
RO	77	Pourtier-Manzanedo, A. et al, " SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhomaine-123 retention within multidrug resistant P388 cells" <i>Anti-Cancer Drugs</i> , 3, pg. 419-425 (1992)
RO	78	Jachaz, B. et al, "SDZ 280-125: a cyclopeptolide endowed with an <i>In vitro</i> cyclosporin A-like profile of activity for the reversion to the P-glycoprotein-mediated multidrug resistance of tumor cells", <i>Anti-Cancer Drugs</i> , 5, pg. 313-320 (1994)
RO	79	Twentyman, Peter R., "Cyclosporins as drug resistance modifiers", <i>Biochemical Pharmacology</i> , 43, pg. 109-117, (1992)
RO	80	Germann, U. et al, "Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP" <i>Anti-Cancer Drugs</i> , 8, pg. 141-155 (1997)
RO	81	Dantzig, A. et al "Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Potent Cyclopropyldibenzosuberance Modulator, LY335979" <i>Cancer Research</i> , 56, pg. 4171-4179, (1996)
RO	82	Starling, J. et al, "Pharmacological Characterization of LY335979: A Potent Cyclopropyldibenzosuberane Modulator of P-Glycoprotein" <i>Advan. Enzym Regul.</i> , 37, pg. 335-347, (1997)
RO	83	Pfister, J. et al, "Methanodibenzosuberilpiperazines as Potent Multidrug Resistance Reversal Agents" <i>Bio rganic & M dicinal Chemistry Letters</i> , 5, pg. 2473-2476 (1995)



COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

P&G Case 8375
FORM PTO-1449
Sheet 6 of 10

OTHER DOCUMENTS Continued 03 2002

RO	84	Klopman, G. et al. "Structure-Activity study and Design of Multidrug-resistant Reversal Compounds by a Computer Automated Structure Evaluation Methodology" <i>Cancer Research</i> , 52, pg. 4121-4129 (1992)
RO	85	Klopman, G. et al. "Quantitative Structure-Activity Relationship of Multidrug-Resistance Reversal Agents" <i>Molecular Pharmacology</i> , 52, pg. 323-334 (1997)
RO	86	Legrand, O. et al. "NEOPLASIA: Simultaneous Activity of MRP1 and Pgp Is Correlated with in vitro resistance to Daunorubicin and with In vivo resistance in Adult Acute Myeloid Leukemia" <i>Blood</i> , 94, pg. 1046-1056 (1999)
RO	87	Leth, C. et al. "NEOPLASIA: Frequency and Clinical Significance of the Expression of the Multidrug resistance proteins MDR1/P-Glycoprotein, MRP1, and LRP in Acute Myeloid Leukemia. A Southwest Oncology Group Study." <i>Blood</i> , 94, pg. 1086-1099 (1999)
RO	88	Mealey, K. et al. "Immunosuppressant inhibition of P-glycoprotein function is independent of drug-induced suppression of Peptide-prolyl isomerase and calcineurin activity" <i>Cancer Chemother Pharmacol</i> , 44, pg. 152-158, (1999)
RO	89	Dey, S. et al. "A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol." <i>Biochemistry</i> , 38, pg. 6630-6639 (1999)
RO	90	Woo, T. et al. "The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface." <i>The Journal of Biological Chemistry</i> , 274, pg. 24759-24765, (1999)
RO	91	Tunggal, J. et al. "Influence of cell concentration in limiting the therapeutic benefit of P-glycoprotein reversal agents" <i>Int. J. Cancer</i> , 81, pg. 741-747 (1999)
RO	92	Zheleznova, E. et al. "A structure-based mechanism for drug binding by multidrug transporters, pg. 39-43, (year)"
RO	93	Di Pierro, A. et al. "P-glycoprotein-mediated resistance to chemotherapy in cancer cells: using recombinant cytosolic domains to establish structure-function relationships" <i>Brazilian J. Med. Biol. Research</i> , 32, pg. 925-939 (1999)
RO	94	Grey, M. et al. "Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in chronic lymphocytic leukaemia" <i>Leukemia Research</i> , 23, pg. 29-35 (1999)
RO	95	Dey, S. et al. "Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein", <i>Proc. Natl. Acad. Sci.</i> , 94, pg. 10594-10599 (1997)
RO	96	Seeling, A. "A general pattern for substrate recognition by P-Glycoprotein" <i>Eur. Journal Biochem.</i> , 251, pg. 252-261 (1998)
RO	97	Tmej, C. et al. "A Combined Hansch/Free-Wilson Approach as Predictive Tool in QSAR Studies on Propafenone-Type Modulators of Multidrug Resistance" <i>Arch. Pharm. Pharm. Med. Chem.</i> , 331, pg. 233-240 (1998)
RO	98	Pearce, H. et al. "Structural characteristics of compounds that modulate P-Glycoprotein-associated multidrug resistance" <i>Advances in Enzyme Regulations</i> , 30, pg. 357-373, (1990)
RO	99	Safa, A. "Photoaffinity Labels for Characterizing Drug Interaction Sites of P-Glycoprotein" <i>Methods in Enzymology</i> , 292, pg. 289-307 (1998)
RO	100	Zhu, B. T. "A Novel Hypothesis for the Mechanism of Action of P-Glycoprotein as a Multidrug Transporter" <i>Molecular Carcinogenesis</i> , 25, pg. 1-13 (1999)
RO	101	Robert, J. "Proposals for Concomitant Use of several modulators of Multidrug Resistance in Clinics" <i>Anticancer Research</i> , 14, pg. 2371-2374 (1994)
RO	102	Hemenway, C et al "Immunosuppressant Target Protein FKBP12 Is Required for P-Glycoprotein Function in Yeast", <i>The Journal of Biological Chemistry</i> , 271, pg. 18527-18534 (1996)
RO	103	Tiberghien, F. et al "Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay" <i>Anti-Cancer Drugs</i> , 7, pg. 568-578 (1996)
RO	104	Scala, S. et al "P-Glycoprotein Substrates and Antagonists Cluster into Two Distinct Groups" <i>Molecular Pharmacology</i> , 51, pg. 1024-1033 (1997)
RO	105	Garrigos, M. et al "Competitive and non-competitive inhibition of the multidrug-resistance associated P-glycoprotein ATPase further experimental evidence for a multisite model" <i>Euro J. Biochem.</i> 244, pg. 664-673 (1997)
RO	106	Litman, T. et al "Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity" <i>Biochimica et Biophysica Acta</i> , 1361, pg. 159-168, (1997)
RO	107	Wiese, M. et al "Molecular modeling study of the multidrug resistance modifiers cis- and trans-flupentixol." <i>Pharmazie</i> , 52, pg. 679-685 (1997)
RO	108	Norman, B. "Inhibitors of MRP1-mediated multidrug resistance" <i>Drugs of the Future</i> , 23, pg. 1001-1013 (1998)
RO	109	Robert, J. "Multidrug resistance reversal agents" <i>Drugs of the Future</i> , 22, pg. 149-158 (1997)
RO	110	Ambudkar, S. et al "Biochemical, Cellular, and Pharmacological Aspects of the multidrug transporter" <i>Annu. Rev. Pharmacol. Toxicol.</i> , 39, pg. 361-398, (1999)
RO	111	Sharom, F. et al "Spectroscopic and biophysical approaches for studying the structure and function of the P-glycoprotein multidrug transporter" <i>Biochim. Biophys. Acta</i> , 1361, pg. 695-708 (1998)



P&G Cas 8375
FORM PTO-1449
Sheet 7 of 10

RECEIVED

OTHER DOCUMENTS Continued

JUL 03 2002

RO	112	Borst, P., "Multidrug resistance: A solvable problem?" <i>Annals of Oncology</i> , 10, pg. S152-S164, (1999)
RO	113	Sonneveld, P., "Drug resistance in Multiple Myeloma" <i>Pathologie & Biologie</i> , 47, pp. 182-187, (1999)
RO	114	Loor, F., "Valspodar: Current status and Perspectives" <i>Expert Opin. Invest. Drugs</i> , 8, pg. 807-835, (1999)
RO	115	Ojima, I. et al "Designing taxanes to treat multidrug-resistant tumors" <i>Mod. in Drug Discovery</i> , pg. 45-52 (1999)
RO	116	Ueda, K. et al "Recent progress in P-Glycoprotein research" <i>Anti-Cancer Drug Design</i> , 14, pg. 115-121 (1999)
RO	117	Ford, J. et al "Pharmacologic circumvention of multidrug resistance" <i>Cytotechnology</i> , 12, pg. 171-212, (1993)
RO	118	Sonneveld, P. et al "Inhibitors of multidrug resistance" <i>Current Opinion in Oncology</i> , 9, pg. 543-548, (1997)
RO	119	Hegewisch-Becker, S., "MDR1 Reversal: Criteria for clinical trials designed to overcome the multidrug resistance phenotype" <i>Leukemia</i> , 10, pg. S32-S38, (1996)
RO	120	Volm, M., "Multidrug Resistance and its Reversal" <i>Anticancer Research</i> , 18, pg. 2905-2918 (1998)
RO	121	Kavallaris, M., "The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance" <i>Anti-Cancer Drugs</i> , 8, pg. 17-25, (1997)
RO	122	Patel, N. et al "Multidrug resistance in cancer chemotherapy" <i>Investigational New Drugs</i> , 12, pg. 1-13, (1994)
RO	123	Hegewisch-Becker, S. et al "The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives" <i>Ann Hematol</i> , 72, pg. 105-117 (1996)
RO	124	Prost, S., "Mechanisms of Resistance to Topoisomerases Poisons" <i>Gen. Pharmac</i> , 26, pg. 1773-1784 (1995)
RO	125	Aszalos, A., "Modulation of Multidrug Resistance in Cancer by Immunosuppressive Agents" <i>Pathology Oncology Research</i> , 1, pg. 64-70, (1995)
RO	126	Tsuruo, T. et al "Multidrug Resistance" <i>Anti-cancer Drugs</i> , 6, pg. 213-218 (1995)
RO	127	Caponigro, F. et al "Protein kinase C: a worthwhile target for anticancer drugs?" <i>Anti-cancer Drugs</i> , 8, pg. 26-33 (1997)
RO	128	Simon, S. et al "Cell biological mechanisms of multidrug resistance in tumors" <i>Proc. Natl. Acad. Sci.</i> , 91, pg. 3497-3504, (1994)
RO	129	Loor, F., "Cyclosporins and Related Fungal Products in the Reversal of P-Glycoprotein-mediated Multidrug resistance" <i>Multidrug Resistance in Cancer Cells</i> , Chapter 26, pg. 385-412, (1996)
RO	130	Lum, B. et al "Molecular Targets in Oncology: Implications of the Multidrug Resistance Gene" <i>Pharmacotherapy</i> 13, pg. 88-109, (1993)
RO	131	Sinha, B., "Topoisomerase Inhibitors" <i>Drugs</i> , 49, pg. 11-19, (1995)
RO	132	Naito, M. et al "New Multidrug-resistance-reversing drugs, MS 209 and SDZ PSC 833" <i>Cancer Chemother Pharmacol</i> , 40, pg. S20-S24, (1997)
RO	133	Ramu, A. et al "Reversal of multidrug resistance by phenothiazines and structurally related compounds" <i>Cancer Chemother Pharmacol</i> , 30, pg. 165-173 (1992)
RO	134	Ramu, A. et al "Reversal of multidrug resistance by bis(phenylalkyl)amines and structurally related compounds" <i>Cancer Chemother Pharmacol</i> , 34, pg. 423-430, (1994)
RO	135	Demeule, M. et al "Inhibition of P-glycoprotein by cyclosporin A analogues and metabolites" <i>Biochem. Cell Biol.</i> , 77, pg. 47-58, (1999)
RO	136	Norman, B. et al "Reversal of Resistance in multidrug resistance protein (MRP1)-overexpressing cells by LY329146." <i>Bioorganic & Medicinal chemistry letters</i> , 9, pg. 3381-3386, (1999)
RO	137	He, H. et al "Fumitremorgin C Analogs that reverse mitoxantrone resistance in human colon carcinoma cells" <i>Med. Chem. Res.</i> , 9, pg. 424-437 (1999)
RO	138	Sparreboom, A. et al "Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein" <i>Anti-Cancer Drugs</i> , 10, pg. 719-728, (1999)
RO	139	Hooijberg, J. et al "Potent interaction of flavopindol with MRP1" <i>British Journal of Cancer</i> , 8, pg. 269-276 (1999)
RO	140	Drewe, J. et al "HIV Protease Inhibitor Ritonavir: A More Potent Inhibitor of P-Glycoprotein than the Cyclosporine Analog SDZ PSC 833" <i>Biochemical Pharmacology</i> , 57, pg. 1147-1152, (1999)
RO	141	Mendez-Vidal, C. et al "Reversal of P-glycoprotein-mediated multidrug resistance in vitro by AV200, a new ardeemin derivative" <i>Cancer Letters</i> , 132, pg. 45-50, (1998)
RO	142	Dantzig, A. et al "Selectivity of the Multidrug Resistance Modulator, LY335979, for P-Glycoprotein and Effect on Cytochrome P-450 Activities" <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 290, pg. 854-862, (1999)
RO	143	Ecker, G. et al "The Importance of a Nitrogen Atom in Modulators of Multidrug resistance" <i>Molecular Pharmacology</i> , 56, pg. 791-796 (1999)
RO	144	Lehne, G. et al "Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents" <i>Leukemia</i> , 13, pg. 768-778 (1999)
RO	145	Regina, A. et al "Dexamethasone Regulation of P-Glycoprotein Activity in an Immortalized Rat Brain Endothelial Cell Line, GPNT" <i>Journal of Neurochemistry</i> , 73, pg. 1954-1963, (1999)

COPY OF PAPERS
ORIGINALLY FILED



RECEIVED

P&G Case 8375
FORM PTO-1449
JUL 03 2002
Sheet 8 of 10

OTHER DOCUMENTS Continued

TECH CENTER 1600/2900

RO	146	Kim, S. et al "Sesquiterpene Esters from <i>Celastrus orbiculatus</i> and their structure-activity relationship on the modulation of multidrug resistance" <i>J. Nat. Prod.</i> , 62, pg. 697-700. (1999)
RO	147	Greenberger, L. et al "A-(3,4-Dimethoxyphenyl)-3,4-dihydro-6,7-dimethoxy-a-[(4-methylphenyl)thio]-2(1H)-iso-quinolineheptanenitrile (CL329,753): A Novel Chemotherapeutic Agent for P-Glycoprotein-Mediated Resistance with Improved Biological Properties Compared with Verapamil and Cyclosporine A" <i>Oncology Research</i> , 8, pg. 207-218. (1996)
RO	148	Nakanishi, O. et al "Potentiation of the Antitumor Activity by a Novel Quinoline Compound, MS-209, in Multidrug-Resistant Solid Tumor Cell Lines", <i>Oncology Research</i> , 9, pg. 61-69 (1997)
RO	149	Kraus-Berthier, L. et al "In Vivo reversal of multidrug resistance by two new dihydropyridine derivatives, S16317 and S16324." <i>Acta Oncologica</i> , 33, pg. 631-637. (1994)
RO	150	Sato, W. et al "Reversal of multidrug resistance by a novel quinoline derivative, MS-209", <i>Cancer Chemother Pharmacol</i> , 35, pg. 271-277 (1995)
RO	151	O'Connell, C. et al "Synthesis and Evaluation of Hapalosin and analogs as MDR-Reversing agents" <i>Bioorganic & Medicinal Chemistry Letters</i> , 9, pg. 1541-1546 (1999)
RO	152	Hail, W. et al "Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance" <i>Biochemical Pharmacology</i> , 43, pg. 103-107. (1992)
RO	153	Liu, Z. et al "BIBW22 BS, Potent Multidrug resistance-Reversing Agent, Binds directly to P-Glycoprotein and Accumulates in Drug-Resistant Cells", <i>Molecular Pharmacology</i> , 50, pg. 482-492. (1996)
RO	154	Kwon, Y. et al "Inhibitors of P-Glycoprotein-mediated Daunomycin Transport in Rat Liver Canalicular Membrane Vesicles" <i>Journal of Pharmaceutical Sciences</i> , 85, pg. 935-939. (1996)
RO	155	Twentyman, P. et al "Effects of cyclosporin A and a non-immunosuppressive analogue, O-acetyl cyclosporin A, upon a growth of parent and multidrug resistant human lung cancer cells <i>in vitro</i> ", <i>Br. J. Cancer</i> , 65, pg. 335-340 (1992)
RO	156	Okuno, T. et al "Chemical Study on Hapalosin, a Cyclic Depsipeptide Possessing Multidrug Resistance Reversing activities: Synthesis, Structure and Biological Activity" <i>Tetrahedron</i> , 52, pg. 14723-14734 (1996)
RO	157	Tanaka, K. et al "Effect of Cyclosporin Analogues and FK506 on Transcellular Transport of Daunorubicin and Vinblastine via P-glycoprotein" <i>Pharmaceutical Research</i> , 13, pg. 1073-1077 (1996)
RO	158	Rao, U. et al "Direct Demonstration of High affinity Interactions of Immunosuppressant Drugs with the Drug Binding Site of the Human P-Glycoprotein" <i>Molecular Pharmacology</i> , 45, pg. 773-776. (1994)
RO	159	Toffoli, G. et al "Reversal activity of Cyclosporin A and its metabolites M1, M17 and M21 in Multidrug-resistant cells" <i>Int. J. Cancer</i> , 71, pg. 900-906 (1997)
RO	160	Demeule, M. et al "Molecular Interactions of Cyclosporin A with P-Glycoprotein" <i>Journal of Biological Chemistry</i> , 272, pg. 6647-6652 (1997)
RO	161	Saeki, T. et al "Human P-glycoprotein transports Cyclosporin A and FK506" <i>The Journal of Biological Chemistry</i> 268 pg. 6077-6080 (1993)
RO	162	Sharom, F. et al "Synthetic hydrophobic peptides are substrates for P-Glycoprotein and stimulate drug transport" <i>Biochem. J.</i> 320, pg. 421-428 (1996)
RO	163	Kim, A. et al, "Saquinavir, an HIV Protease Inhibitor, Is Transported by P-Glycoprotein" <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 266, pg. 1439-1445 (1998)
RO	164	Chiba, P. et al "Studies on propafenone-type modulators of multidrug resistance VI. Synthesis and pharmacological activity of compounds with varied spacer length between the central aromatic ring and the nitrogen atom" <i>Il Farmaco</i> , 53, pg. 357-364 (1998)
RO	165	Motohashi, N. et al "Drug Resistance Reversal, Anti-mutagenicity and Antiretroviral Effect of Phthalimido- and Chloroethyl-Phenothiazines" <i>Anticancer Research</i> , 17, pg. 3537-3544 (1997)
RO	166	De Jong, G. et al "Modulation of Doxorubicin Resistance in P388 ADR Cells by Ro44-5912, a Tiapamil Derivative" <i>Anticancer Research</i> , 15, pg. 911-916 (1995)
RO	167	Campolongo, L. et al "Reversal of multidrug resistance by new dihydropyridines with low calcium antagonist activity" <i>Acta Oncologica</i> 33, pg. 787-791 (1994)
RO	168	Etievant, C. et al "Requirements for P-glycoprotein recognition based on structure-activity relationships in the podophyllotoxin series" <i>Anti-Cancer Drug Design</i> 13, pg. 317-336 (1998)
RO	169	Shrivastava, P. et al "Circumvention of multidrug resistance by a quinoline derivative, MS-209, in multidrug-resistant human small-cell lung cancer cells and its synergistic interaction with cyclosporin A or verapamil" <i>Cancer Chemother Pharmacol</i> 42, pg. 483-490 (1998)
RO	170	Yang, J. et al "Inhibitory Effect of Alkylating Modulators on the Function of P-Glycoprotein" <i>Oncology Research</i> , 9, pg. 477-484. (1997)
RO	171	Thimmaiah, K. et al "Characterization of 2-Chloro-N ¹⁰ -Substituted Phenoxazines for Reversing Multidrug Resistance in Cancer cells" <i>Oncology Research</i> , 10, pg. 29-41. (1998)
RO	172	Naito, S. et al "Development of Novel Reversal Agents, Imidazothiazole Derivatives, targeting MDR1 and MRP-Mediated Multidrug Resistance." <i>Oncology Research</i> , 10, pg. 123-132 (1998)
RO	173	Ramu, N. et al "Circumvention of Adriamycin Resistance by Dipyrindimole Analogues: a structure-activity relationship study" <i>Int. J. Cancer</i> , 43, pg. 487-491. (1989)

COPY OF PAPERS
ORIGINALLY FILED



RECEIVED P&G Case 8375
FORM PTO-1449
JUL 03 2002 Sheet 9 of 10

OTHER DOCUMENTS Continued

TECH CENTER 1600/2900

Ro	174	Hill, B. et al "Evaluation of S9788 as a Potential Modulator of Drug Resistance against Human Tumour Sublines Expressing Differing Resistance Mechanisms <i>in vitro</i> " Int. J. Cancer , 55, pg. 330-337 (1993)
Ro	175	Sato, S. et al "Potentiation of vincristine and antinomycin D by a new synthetic imidazole anti-tumor agent YM534 active against human cancer cells and multidrug-resistant cells" Anti-Cancer Drug Design , 4, pg. 125-135. (1989)
Ro	176	Narasaki, F. et al "A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene" Cancer Chemother Pharmacol , 40, pg. 425-432 (1997)
Ro	177	Takeshita, H. et al "Avoidance of Doxorubicin Resistance in Osteosarcoma Cells Using a New Quinoline Derivative, MS-209" Anticancer Research , 18, pg. 739-742 (1998)
Ro	178	Boer, R. et al "Modulation of P-glycoprotein Mediated Drug Accumulation in Multidrug Resistant CCRF VCR-1000 Cells by Chemosensitisers" European Journal of Cancer , 32A, pg. 857-861 (1996)
Ro	179	Van Rensburg, C. et al, "Novel tetramethylpiperidine-substituted phenazines are potent inhibitors of P-glycoprotein activity in a multidrug resistant cancer cell line" Anticancer Drugs , 8, pg. 708-713 (1997)
Ro	180	Choi, S. et al "The bisbenzylisoquinoline alkaloids, tetrastine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein." Anticancer Drugs , 9, pg. 255-261 (1998)
Ro	181	Abderrabi, M. et al "Comparative <i>in vitro</i> evaluation of dithiane analogs of tiapamil, Ro 11-2933, Ro 44-5911 and Ro 44-5912 as multidrug resistance modulators" Anti-Cancer Drugs , 7, pg. 430-436 (1996)
Ro	182	Kim, S. et al "Circumvention of drug resistance in cancer cells by a new fluoropyrimidine analogue" Experimental and molecular Medicine , 28, pg. 119-123, (1996)
Ro	183	Christensen, J. et al "Reversal of multidrug resistance by derivatives of acrivastine: a study of structure-activity relationships of P-glycoprotein inhibitors <i>in vitro</i> and <i>in vivo</i> " Oncology Reports , 4, pg. 1353-1360 (1997)
Ro	184	Thimmaiah, K. et al "Structural Determinants of Phenoxazine Type Compounds Required to Modulate the Accumulation of Vinblastine and Vincristine in Multidrug-resistant cell lines" Cancer Communications , 2, pg. 249-259, (1990)
Ro	185	Smith, A. et al "Availability of PSC833, a Substrate and Inhibitor of P-Glycoproteins, in Various Concentrations of Serum" Journal of the National Cancer Institute , 90, pg. 1161-1166, (1998)
Ro	186	Seppro, J. et al "Peptide derivatives Against Multidrug Resistance" Peptides, Proceedings of the 24th European Peptide Symposium , pg. 801-802, (1996)
Ro	187	Suzuki, T. et al "Structure-Activity Relationship of Newly Synthesized Quinoline derivatives for Reversal of Multidrug Resistance in Cancer" J. Med. Chem. , 40, pg. 2047-2052 (1997)
Ro	188	Chiba, P. et al "Substituted 4-Acylpyrazoles and 4-Acylpyrazolones" Synthesis and Multidrug Resistance-Modulating Activity" J. Med. Chem. , 41, pg. 4001-4011 (1998)
Ro	189	Suzuki, T. et al "Synthesis of Glucuronides of multidrug resistance Reversing Drug MS-209" Bioorganic & Medicinal Chemistry Letters , 9, pg. 659-662 (1999)
Ro	190	Nakamura, S. et al "Effects of Isoquinolinesulphonamide Compounds on Multidrug-resistant P388 cells" J. Pharm. Pharmacol 45, pg. 268-273 (1993)
Ro	190	Ogino, J. et al "Dendroamides, New Cyclic Hexapeptides from a Blue-Green Alga. Multidrug-Resistance Reversing activity of dendroamide A." J. Nat. Prod. , 59, pg. 581-586 (1996)
Ro	191	Kim, E. et al, "A New Sesquiterpene Ester from <i>Celastrus orbiculatus</i> Reversing Multidrug Resistance in cancer Cells" J. Nat. Prod. , 61, pg. 108-111 (1998)
Ro	192	Lehnert, M. et al "Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer" British Journal of Cancer 77, pg. 1155-1163 (1998)
Ro	193	Dale, I et al "Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative" British Journal of Cancer , 78, pg. 885-892 (1998)
Ro	194	Budworth, J. et al "Comparison of Staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug resistant MCF-7/Adr cells" British Journal of Cancer , 73, pg. 1063-1068 (1996)
Ro	195	Hurwitz, L. et al "Can prenylcysteines be exploited as ligands for mammalian multidrug-resistance transporters?" Chemistry & Biology , 4, pg. 711-715 (1997)
Ro	196	Gekeler, V. et al "Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF109203X on P-glycoprotein-mediated multidrug resistance" British Journal of Cancer , 74, pg. 897-905 (1996)
Ro	197	Newman, R. et al "MDL 201307: a novel benzothiazepine modulator of multiple drug resistance" Journal of Experimental Therapeutics & Oncology , 1, pg. 109-118 (1996)
Ro	198	Jachez, B. et al "SDZ 280-125: a cyclopeptide endowed with an <i>in vitro</i> cyclosporin A-like profile of activity for the reversion of the P-glycoprotein-mediated multidrug resistance of tumor cells" Anti-cancer drugs , 5, pg. 313-320 (1994)
Ro	199	Jachetz, B. et al "Reversion of the P-glycoprotein-mediated multidrug resistance of cancer cells by FK-506 derivatives" Anti-cancer Drugs , 4, pg. 223-229 (1993)
Ro	200	Fan, D. et al "Reversal of multidrug resistance in murine fibrosarcoma cells by thioxanthene flupentixol" Investigational New Drugs , 12, pg. 185-195, (1994)

COPY OF PAPERS
ORIGINALLY FILED



RECEIVED P&G Case 8375
FORM PTO-1449
Sheet 10 of 10

OTHER DOCUMENTS Continued


JUL 03 2002

RA	201	Molnar, J. et al "Inhibition of the Transport Function of Membrane Phenothiazines in E. Coli and Multidrug Resistant Tumor Cells" <i>Anticancer Research</i> , 17, pg. 481-486 (1997)
RA	202	Teodori, E. et al "D sign, Synth sis, and in Vitro Activity of Catamphiphilic reverts of Multidrug Resistance: Discovery of a Selective, Highly Efficacious Chemosensitizer with Potency in the Nanomolar Range" <i>J. Med. Chem.</i> , 42, pg. 1687-1697, (1999)
RA	203	Van Asperen, J. et al "The Pharmacological Role of P-Glycoprotein in the Intestinal Epithelium", <i>The Italian Pharmacological Society</i> , (1998)
RA	204	Wacher, V. et al "Role of P-Glycoprotein and Cytochrome P450 3A in Limiting Oral Absorption of Peptid s and Peptidomimetics" <i>Journal of Pharmaceutical Sciences</i> 87, pg. 1322-1330, (1998)
RA	205	Matsuzaki, J. et al "Contribution of P-glycoprotein to Bunitrolol Efflux across Blood-Brain Barrier" <i>Biopharaceutics and Drug Disposition</i> , 20, pg. 85-90(1999)
RA	206	Sanglard, D. et al "Mechanisms of Resistance to azole Antifungal Agents in Candida albicans Isolates from AIDS Patients Involve Specific Multidrug Transporters" <i>Antimicrobial Agents and Chemotherapy</i> , 39,, pg. 2378-2386 (1995)
RA	207	Li, X. et al "Role of Efflux Pump(s) in Intrinsic Resistance of Pseudomonas aeruginosa: Active Efflux as a contributing Factor a B-Lactam Resistance" <i>Antimicrobial Agents and Chemotherapy</i> , 38, pg. 1742-1752 (1994)
RA	208	Van Veen, H. et al "The ABC family of multidrug transporters in microorganisms" <i>Biochimica et Biophysica Acta</i> , 1365, pg. 31-36 (1998)
RA	209	Kim, A. et al "Saquinavir, an HIV Protease Inhibitor, Is Transported by P-Glycoprotein", <i>Journal Pharm. And Experimental Therapeutics</i> , 286, pg. 1439-1445 (1998)
RA	210	Lee, I. et al "Protease Inhibitors and the MDR1 Multidrug Transporter" <i>The Journal of Clinical Investigation</i> , 101, pg. 287-288 (1998)
RA	211	Renau, T. et al "Chapter 12. Antimicrobial Potentiation Approaches: Targets and Inhibitors" <i>annual Reports in Mediclnal Chemistry</i> , 33, pg. 121-129 (1998)
EXAMINER		DATE CONSIDERED
RDesai		11-14-2002
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Patent and Trademark Office - U.S. DEPARTMENT OF COMMERCE

COPY OF PAPERS
ORIGINALLY FILED

Please type a plus sign (+) inside this box → [+]



PTO/SB08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p> <p>SHEET 1 of 1</p>	COMPLETE IF KNOWN	
	Application Number	09/996,657
	Confirmation Number	6277
	Filing Date	November 29, 2001
	First Named Inventor	Degenhardt et al.
	Group Art Unit	1625
	Examiner Name	R. Desai
Attorney Docket Number		8375D

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
Ra	1	WO 00/50418 A1	08-31-2000	Fournier Industrie et Sante		
RO	2	WO 00/32588 A2	06-08-2000	GPI NIL Holdings, Inc. & Amgen Inc.		
Ro	3	WO 00/01714 A1	01-13-2000	Microcide Pharmaceuticals, Inc. & Daiich Pharmaceutical Co., Ltd.		
Ro	4	JP 09 12,577	01-14-1997	Takedo Chemical Indus. Ltd.	(Abstract Only)	
RO	5	WO 92/18478 A1	10-29-1992	Boehringer Mannheim Italia S.P.A.		
Ro	6	WO 94/07856 A1	04-14-1994	Boehringer Mannheim Italia S.P.A.		
Ro	7	WO 01/74769 A1	10-11-2001	Applied Research Systems ARS Holding N.V.		
Ro	8	WO 01/58891 A2	08-16-2001	Vertex Pharmaceuticals Inc.		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
EXAMINER	R. Desai		DATE CONSIDERED 11-14-2002

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.